miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents

Current Cancer Drug Targets

Volumn 13, Issue 5, 2013, Pages 519-541

  Qian, Biyun ^a   Nag, Subhasree A ^b   Su, Yuliang ^a   Voruganti, Sukesh ^b   Qin, Jiang Jiang ^b   Zhang, Ruiwen ^b   Cho, William C S ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Biomarker; Cancer diagnosis; Cancer prognosis; Cancer therapy; Chemoprevention; Epigenetics; MicroRNA; Natural product; Oncogene; Tumor suppressor gene

Indexed keywords

3 INDOLEMETHANOL; BIOLOGICAL MARKER; BOSTRYCIN; CETUXIMAB; CURCUMIN; CYCLIN DEPENDENT KINASE 2; EPIGALLOCATECHIN GALLATE; ERGOCALCIFEROL; ESTROGEN RECEPTOR; GINSENOSIDE RH 2; INOSITOL; ISOFLAVONE; MATRINE; MICRORNA; MICRORNA 155; MICRORNA 17; MICRORNA 18A; MICRORNA 19A; MICRORNA 19B; MICRORNA 20A; MICRORNA 21; MICRORNA 92; PHENETHYL ISOTHIOCYANATE; RAS PROTEIN; RESVERATROL; RETINOL; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN B GROUP;

3' UNTRANSLATED REGION; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENE EXPRESSION; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); NEOPLASM; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKE; TRANSLATIONAL RESEARCH; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHYTOTHERAPY; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84882586963     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990031     Document Type: Review

References (268)

1. Lee, R. C.; Feinbaum, R. L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75 (5), 843-854.
2. Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75 (5), 855-862.
3. Lee, Y.; Kim, M.; Han, J.; Yeom, K. H.; Lee, S.; Baek, S. H.; Kim, V. N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23 (20), 4051-4060.
4. Krol, J.; Loedige, I.; Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010,11 (9), 597-610.
5. Zhao, L.; Bode, A. M.; Cao, Y.; Dong, Z., Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis 2012, 33 (11), 2220-7.
6. Iorio, M. V.; Croce, C. M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2012, 4 (3), 143-159.
7. Kozomara, A.; Griffiths-Jones, S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39 (Database issue), D152-D157.
8. Calin, G. A.; Dumitru, C. D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C. M. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99 (24), 15524-15529.
9. Cimmino, A.; Calin, G. A.; Fabbri, M.; Iorio, M. V.; Ferracin, M.; Shimizu, M.; Wojcik, S. E.; Aqeilan, R. I.; Zupo, S.; Dono, M.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C. G.; Kipps, T. J.; Negrini, M.; Croce, C. M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U S A 2005, 102 (39), 13944-13949.
10. Cho, W. C. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 2007, 6, 60.
11. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S. T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133 (2), 647-658.
12. Zhu, S.; Si, M. L.; Wu, H.; Mo, Y. Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 2007, 282 (19), 14328-14236.
13. Asangani, I. A.; Rasheed, S. A.; Nikolova, D. A.; Leupold, J. H.; Colburn, N. H.; Post, S.; Allgayer, H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27 (15), 2128-2136.
14. Frankel, L. B.; Christoffersen, N. R.; Jacobsen, A.; Lindow, M.; Krogh, A.; Lund, A. H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008, 283 (2), 1026-1033.
15. Ren, Y.; Zhou, X.; Mei, M.; Yuan, X.B.; Han, L.; Wang, G. X.; Jia, Z. F.; Xu, P.; Pu, P. Y.; Kang, C. S. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010, 10, 27.
16. Si, M. L.; Zhu, S.; Wu, H.; Lu, Z.; Wu, F.; Mo, Y. Y. miR-21-mediated tumor growth. Oncogene 2007, 26 (19), 2799-2803
17. Zhang, A.; Liu, Y.; Shen, Y.; Xu, Y.; Li, X., miR-21 modulates cell apoptosis by targeting multiple genes in renal cell carcinoma. Urology 2011, 78 (2), 474.e13-e19.
18. Haider, K. H.; Idris, N. M.; Kim, H. W.; Ahmed, R. P.; Shujia, J.; Ashraf, M. MicroRNA-21 is a key determinant in IL-11/Stat3 anti-apoptotic signalling pathway in preconditioning of skeletal myoblasts. Cardiovasc. Res. 2010, 88 (1), 168-178.
19. Liu, L. Z.; Li, C.; Chen, Q.; Jing, Y.; Carpenter, R.; Jiang, Y.; Kung, H. F.; Lai, L.; Jiang, B. H. miR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PloS One 2011, 6 (4), e19139.
20. Frezzetti, D.; De Menna, M.; Zoppoli, P.; Guerra, C.; Ferraro, A.; Bello, A. M.; De Luca, P.; Calabrese, C.; Fusco, A.; Ceccarelli, M.; Zollo, M.; Barbacid, M.; Di Lauro, R.; De Vita, G. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 2011, 30 (3), 275-286.
21. Cao, Z.; Yoon, J. H.; Nam, S. W.; Lee, J. Y.; Park, W. S. PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. J. Cancer Res. Clin. Oncol. 2012, 138 (4), 611-619.
22. Medina, P. P.; Nolde, M.; Slack, F. J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467(7311), 86-90.
23. Li, Y.; Li, W.; Yang, Y.; Lu, Y.; He, C.; Hu, G.; Liu, H.; Chen, J.; He, J.; Yu, H. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res. 2009, 1286, 13-18.
24. Gao, G.; Gay, H. A.; Chernock, R. D.; Zhang, T. R.; Luo, J.; Thorstad, W. L.; Lewis, J. S., Jr.; Wang, X. A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer 2012. [Epub ahead of print].
25. Mavrakis, K. J.; Wolfe, A. L.; Oricchio, E.; Palomero, T.; de Keersmaecker, K.; McJunkin, K.; Zuber, J.; James, T.; Khan, A. A.; Leslie, C. S.; Parker, J. S.; Paddison, P. J.; Tam, W.; Ferrando, A.; Wendel, H. G. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat. Cell Biol. 2010, 12 (4), 372-379.
26. Mendell, J. T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008, 133 (2), 217-222.
27. Dews, M.; Homayouni, A.; Yu, D.; Murphy, D.; Sevignani, C.; Wentzel, E.; Furth, E. E.; Lee, W. M.; Enders, G. H.; Mendell, J. T.; Thomas-Tikhonenko, A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 2006, 38 (9), 1060-1065.
28. Northcott, P. A.; Fernandez, L. A.; Hagan, J. P.; Ellison, D. W.; Grajkowska, W.; Gillespie, Y.; Grundy, R.; Van Meter, T.; Rutka, J. T.; Croce, C. M.; Kenney, A. M.; Taylor, M. D. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 2009, 69 (8), 3249-3255.
29. Woods, K.; Thomson, J. M.; Hammond, S. M. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J. Biol. Chem. 2007, 282 (4), 2130-2134.
30. Greither, T.; Grochola, L. F.; Udelnow, A.; Lautenschlager, C.; Wurl, P.; Taubert, H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer. 2010, 126 (1), 73-80.
31. Gironella, M.; Seux, M.; Xie, M. J.; Cano, C.; Tomasini, R.; Gommeaux, J.; Garcia, S.; Nowak, J.; Yeung, M. L.; Jeang, K. T.; Chaix, A.; Fazli, L.; Motoo, Y.; Wang, Q.; Rocchi, P.; Russo, A.; Gleave, M.; Dagorn, J. C.; Iovanna, J. L.; Carrier, A.; Pebusque, M. J.; Dusetti, N. J. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. U S A 2007, 104 (41), 16170-16175.
32. Iorio, M. V.; Ferracin, M.; Liu, C. G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; Menard, S.; Palazzo, J. P.; Rosenberg, A.; Musiani, P.; Volinia, S.; Nenci, I.; Calin, G. A.; Querzoli, P.; Negrini, M.; Croce, C. M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65 (16), 7065-7070.
33. Johnson, C. D.; Esquela-Kerscher, A.; Stefani, G.; Byrom, M.; Kelnar, K.; Ovcharenko, D.; Wilson, M.; Wang, X.; Shelton, J.; Shingara, J.; Chin, L.; Brown, D.; Slack, F. J. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007, 67 (16), 7713-7722.
34. Bussing, I.; Slack, F. J.; Grosshans, H. Let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med. 2008, 14 (9), 400-409.
35. Roush, S.; Slack, F. J. The let-7 family of microRNAs. Trends Cell Biol. 2008, 18 (10), 505-516.
36. Barh, D.; Malhotra, R.; Ravi, B.; Sindhurani, P. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr. Oncol. 2010, 17 (1), 70-80.
37. Johnson, S. M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K. L.; Brown, D.; Slack, F. J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120 (5), 635-647.
38. Calin, G. A.; Cimmino, A.; Fabbri, M.; Ferracin, M.; Wojcik, S. E.; Shimizu, M.; Taccioli, C.; Zanesi, N.; Garzon, R.; Aqeilan, R. I.; Alder, H.; Volinia, S.; Rassenti, L.; Liu, X.; Liu, C. G.; Kipps, T. J.; Negrini, M.; Croce, C. M. miR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl. Acad. Sci. USA 2008, 105 (13), 5166-5171.
39. Takeshita, F.; Patrawala, L.; Osaki, M.; Takahashi, R. U.; Yamamoto, Y.; Kosaka, N.; Kawamata, M.; Kelnar, K.; Bader, A. G.; Brown, D.; Ochiya, T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18 (1), 181-187.
40. Bonci, D.; Coppola, V.; Musumeci, M.; Addario, A.; Giuffrida, R.; Memeo, L.; D'Urso, L.; Pagliuca, A.; Biffoni, M.; Labbaye, C.; Bartucci, M.; Muto, G.; Peschle, C.; De Maria, R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14 (11), 1271-1277.
41. Yin, K. J.; Olsen, K.; Hamblin, M.; Zhang, J.; Schwendeman, S. P.; Chen, Y. E. Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia. J. Biol. Chem. 2012, 287 (32), 27055-27064.
42. Chang, T. C.; Wentzel, E. A.; Kent, O. A.; Ramachandran, K.; Mullendore, M.; Lee, K. H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.; Lowenstein, C. J.; Arking, D. E.; Beer, M. A.; Maitra, A.; Mendell, J. T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26 (5), 745-752.
43. Cole, K. A.; Attiyeh, E. F.; Mosse, Y. P.; Laquaglia, M. J.; Diskin, S. J.; Brodeur, G. M.; Maris, J. M. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res. 2008, 6 (5), 735-742.
44. Yamakuchi, M.; Lowenstein, C. J. miR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009, 8 (5), 712-715.
45. Ji, Q.; Hao, X.; Zhang, M.; Tang, W.; Yang, M.; Li, L.; Xiang, D.; Desano, J. T.; Bommer, G. T.; Fan, D.; Fearon, E. R.; Lawrence, T. S.; Xu, L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PloS One 2009, 4 (8), e6816.
46. Keklikoglou, I.; Koerner, C.; Schmidt, C.; Zhang, J. D.; Heckmann, D.; Shavinskaya, A.; Allgayer, H.; Guckel, B.; Fehm, T.; Schneeweiss, A.; Sahin, O.; Wiemann, S.; Tschulena, U. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene 2012, 31(37), 4150-4163.
47. Ivanovska, I.; Cleary, M. A. Combinatorial microRNAs: working together to make a difference. Cell Cycle 2008, 7 (20), 3137-3142.
48. Lytle, J. R.; Yario, T. A.; Steitz, J. A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc. Natl. Acad. Sci. USA 2007, 104 (23), 9667-9672.
49. Moretti, F.; Thermann, R.; Hentze, M. W. Mechanism of translational regulation by miR-2 from sites in the 5' untranslated region or the open reading frame. RNA 2010, 16 (12), 2493-2502.
50. Orom, U. A.; Nielsen, F. C.; Lund, A. H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 2008, 30 (4), 460-471.
51. Issabekova, A.; Berillo, O.; Regnier, M.; Anatoly, I. Interactions of intergenic microRNAs with mRNAs of genes involved in carcinogenesis. Bioinformation 2012, 8(11), 513-518.
52. Salmena, L.; Poliseno, L.; Tay, Y.; Kats, L.; Pandolfi, P. P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011, 146 (3), 353-358.
53. Tay, Y.; Kats, L.; Salmena, L.; Weiss, D.; Tan, S. M.; Ala, U.; Karreth, F.; Poliseno, L.; Provero, P.; Di Cunto, F.; Lieberman, J.; Rigoutsos, I.; Pandolfi, P. P. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147 (2), 344-357.
54. Cesana, M.; Cacchiarelli, D.; Legnini, I.; Santini, T.; Sthandier, O.; Chinappi, M.; Tramontano, A.; Bozzoni, I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147 (2), 358-369.
55. Hurst, D. R.; Edmonds, M. D.; Welch, D. R. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009, 69 (19), 7495-7498.
56. Lopez-Camarillo, C.; Marchat, L. A.; Arechaga-Ocampo, E.; Perez-Plasencia, C.; Del Moral-Hernandez, O.; Castaneda-Ortiz, E. J.; Rodriguez-Cuevas, S. MetastamiRs: Non-Coding MicroRNAs Driving Cancer Invasion and Metastasis. Int. J. Mol. Sci. 2012, 13 (2), 1347-1379.
57. White, N. M.; Fatoohi, E.; Metias, M.; Jung, K.; Stephan, C.; Yousef, G. M. Metastamirs: a stepping stone towards improved cancer management. Nat. Rev. Clin. Oncol. 2011, 8 (2), 75-84.
58. Brabletz, S.; Bajdak, K.; Meidhof, S.; Burk, U.; Niedermann, G.; Firat, E.; Wellner, U.; Dimmler, A.; Faller, G.; Schubert, J.; Brabletz, T. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011, 30 (4), 770-782.
59. Hur, K.; Toiyama, Y.; Takahashi, M.; Balaguer, F.; Nagasaka, T.; Koike, J.; Hemmi, H.; Koi, M.; Boland, C. R.; Goel, A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2012. [Epub ahead of print]
60. Ma, L.; Teruya-Feldstein, J.; Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449 (7163), 682-688.
61. Vetter, G.; Saumet, A.; Moes, M.; Vallar, L.; Le Bechec, A.; Laurini, C.; Sabbah, M.; Arar, K.; Theillet, C.; Lecellier, C. H.; Friederich, E. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene 2010, 29 (31), 4436-4448.
62. Cottonham, C. L.; Kaneko, S.; Xu, L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J. Biol. Chem. 2010, 285 (46), 35293-35302.
63. Kong, W.; Yang, H.; He, L.; Zhao, J. J.; Coppola, D.; Dalton, W. S.; Cheng, J. Q. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell Biol. 2008, 28 (22), 6773-6784.
64. Le, X. F.; Merchant, O.; Bast, R. C.; Calin, G. A. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron. 2010, 3 (1), 137-147.
65. Permuth-Wey, J.; Chen, Z.; Tsai, Y. Y.; Lin, H. Y.; Chen, Y. A.; Barnholtz-Sloan, J.; Birrer, M. J.; Chanock, S. J.; Cramer, D. W.; Cunningham, J. M.; Fenstermacher, D.; Fridley, B. L.; Garcia-Closas, M.; Gayther, S. A.; Gentry-Maharaj, A.; Gonzalez-Bosquet, J.; Iversen, E.; Jim, H.; McLaughlin, J.; Menon, U.; Narod, S. A.; Phelan, C. M.; Ramus, S. J.; Risch, H.; Song, H.; Sutphen, R.; Terry, K. L.; Tyrer, J.; Vierkant, R. A.; Wentzensen, N.; Lancaster, J. M.; Cheng, J. Q.; Berchuck, A.; Pharoah, P. D.; Schildkraut, J. M.; Goode, E. L.; Sellers, T. A. MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol. Biomarkers Prev. 2011, 20 (8), 1793-1797.
66. Horikawa, Y.; Wood, C. G.; Yang, H.; Zhao, H.; Ye, Y.; Gu, J.; Lin, J.; Habuchi, T.; Wu, X. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin. Cancer Res. 2008, 14 (23), 7956-7962.
67. Liang, D.; Meyer, L.; Chang, D. W.; Lin, J.; Pu, X.; Ye, Y.; Gu, J.; Wu, X.; Lu, K. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res. 2010, 70 (23), 9765-9776.
68. Slaby, O.; Bienertova-Vasku, J.; Svoboda, M.; Vyzula, R. Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J. Cell. Mol. Med. 2012, 16 (1), 8-21.
69. Sun, G.; Yan, J.; Noltner, K.; Feng, J.; Li, H.; Sarkis, D. A.; Sommer, S. S.; Rossi, J. J. SNPs in human miRNA genes affect biogenesis and function. RNA 2009, 15 (9), 1640-1651.
70. Tian, T.; Shu, Y.; Chen, J.; Hu, Z.; Xu, L.; Jin, G.; Liang, J.; Liu, P.; Zhou, X.; Miao, R.; Ma, H.; Chen, Y.; Shen, H. A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol. Biomarkers Prev. 2009, 18 (4), 1183-1187.
71. Hoffman, A. E.; Zheng, T.; Yi, C.; Leaderer, D.; Weidhaas, J.; Slack, F.; Zhang, Y.; Paranjape, T.; Zhu, Y. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res. 2009, 69 (14), 5970-5977.
72. Peng, S.; Kuang, Z.; Sheng, C.; Zhang, Y.; Xu, H.; Cheng, Q. Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig. Dis. Sci. 2010, 55 (8), 2288-2293.
73. Christensen, B. C.; Avissar-Whiting, M.; Ouellet, L. G.; Butler, R. A.; Nelson, H. H.; McClean, M. D.; Marsit, C. J.; Kelsey, K. T. Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin. Cancer Res. 2010, 16 (14), 3713-3720.
74. Akkiz, H.; Bayram, S.; Bekar, A.; Akgollu, E.; Ulger, Y. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J. Viral. Hepat. 2011, 18 (7), e399-407.
75. Chu, Y. H.; Tzeng, S. L.; Lin, C. W.; Chien, M. H.; Chen, M. K.; Yang, S. F. Impacts of microRNA gene polymorphisms on the susceptibility of environmental factors leading to carcinogenesis in oral cancer. PLoS One 2012, 7 (6), e39777.
76. Wang, F.; Ma, Y. L.; Zhang, P.; Yang, J. J.; Chen, H. Q.; Liu, Z. H.; Peng, J. Y.; Zhou, Y. K.; Qin, H. L. A genetic variant in microRNA-196a2 is associated with increased cancer risk: a meta-analysis. Mol. Biol. Rep. 2012, 39 (1), 269-275.
77. Wang, J.; Wang, Q.; Liu, H.; Shao, N.; Tan, B.; Zhang, G.; Wang, K.; Jia, Y.; Ma, W.; Wang, N.; Cheng, Y. The association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis 2012, 27 (6), 779-788.
78. Wang, P.; Xie, S.; Cui, A.; Zhang, Y.; Jiang, B. miR-196a2 polymorphisms and susceptibility to cancer: A meta-analysis involving 24,697 subjects. Exp. Ther. Med. 2012, 3 (2), 324-330.
79. Guo, J.; Jin, M.; Zhang, M.; Chen, K. A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. PLoS One 2012, 7 (1), e30585.
80. Xu, W.; Xu, J.; Liu, S.; Chen, B.; Wang, X.; Li, Y.; Qian, Y.; Zhao, W.; Wu, J. Effects of common polymorphisms rs11614913 in miR-196a2 and rs2910164 in miR-146a on cancer susceptibility: a meta-analysis. PLoS One 2011, 6 (5), e20471.
81. Chu H.; Wang, M.; Shi, D.; Ma, L.; Zhang, Z.; Tong, N.; Huo, X.; Wang, W.; Luo, D.; Gao, Y. Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies. PLoS One 2011, 6 (3), e18108.
82. Wang, Z.; Cao, Y.; Jiang, C.; Yang, G.; Wu, J.; Ding, Y. Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS One 2012, 7 (6), e40039.
83. Gao, L. B.; Bai, P.; Pan, X. M.; Jia, J.; Li, L. J.; Liang, W. B.; Tang, M.; Zhang, L. S.; Wei, Y. G.; Zhang, L. The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 2011, 125 (2), 571-574.
84. Tian, T.; Xu, Y.; Dai, J.; Wu, J.; Shen, H.; Hu, Z. Functional polymorphisms in two pre-microRNAs and cancer risk: a meta-analysis. Int. J. Mol. Epidemiol. Genet. 2010, 1 (4), 358-366.
85. Qiu, L. X.; He, J.; Wang, M. Y.; Zhang, R. X.; Shi, T. Y.; Zhu, M. L.; Mao, C.; Sun, S.; Lv, F. F.; Zheng, C. L.; Zhu, X. D. The association between common genetic variant of microRNA-146a and cancer susceptibility. Cytokine 2011, 56 (3), 695-698.
86. Wang, J.; Bi, J.; Liu, X.; Li, K.; Di, J.; Wang, B. Hsa-miR-146a polymorphism (rs2910164) and cancer risk: a meta-analysis of 19 case-control studies. Mol. Biol. Rep. 2012, 39 (4), 4571-4579.
87. Wang, F.; Sun, G.; Zou, Y.; Fan, L.; Song, B. Lack of association of miR-146a rs2910164 polymorphism with gastrointestinal cancers: evidence from 10206 subjects. PLoS One 2012, 7 (6), e39623.
88. Lian, H.; Wang, L.; Zhang, J. Increased risk of breast cancer associated with CC genotype of Has-miR-146a Rs2910164 polymorphism in Europeans. PLoS One 2012, 7 (2), e31615.
89. Wang, F.; Sun, G.; Zou, Y.; Li, Y.; Hao, L.; Pan, F. Association of microRNA-499 rs3746444 Polymorphism with Cancer Risk: Evidence from 7188 Cases and 8548 Controls. PLoS One 2012, 7 (9), e45042.
90. Wang, Y.; Yang, B.; Ren, X. Hsa-miR-499 polymorphism (rs3746444) and cancer risk: A meta-analysis of 17 case-control studies. Gene 2012, 509 (2), 267-272.
91. Wang, L.; Qian, S.; Zhi, H.; Zhang, Y.; Wang, B.; Lu, Z. The association between hsa-miR-499 T>C polymorphism and cancer risk: A meta-analysis. Gene 2012, 508 (1), 9-14.
92. Yu, Z.; Li, Z.; Jolicoeur, N.; Zhang, L.; Fortin, Y.; Wang, E.; Wu, M.; Shen, S. H. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res. 2007, 35 (13), 4535-4541.
93. Pelletier, C.; Weidhaas, J. B. MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev. Mol. Diagn. 2010, 10 (6), 817-829.
94. Chin, L. J.; Ratner, E.; Leng, S.; Zhai, R.; Nallur, S.; Babar, I.; Muller, R. U.; Straka, E.; Su, L.; Burki, E. A.; Crowell, R. E.; Patel, R.; Kulkarni, T.; Homer, R.; Zelterman, D.; Kidd, K. K.; Zhu, Y.; Christiani, D. C.; Belinsky, S. A.; Slack, F. J.; Weidhaas, J. B. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008, 68 (20), 8535-8540.
95. Christensen, B. C.; Moyer, B. J.; Avissar, M.; Ouellet, L. G.; Plaza, S. L.; McClean, M. D.; Marsit, C. J.; Kelsey, K. T. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009, 30 (6), 1003-1007.
96. Zhang, W.; Winder, T.; Ning, Y.; Pohl, A.; Yang, D.; Kahn, M.; Lurje, G.; Labonte, M. J.; Wilson, P. M.; Gordon, M. A.; Hu-Lieskovan, S.; Mauro, D. J.; Langer, C.; Rowinsky, E. K.; Lenz, H. J. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann. Oncol. 2011, 22 (1), 104-109.
97. Smits, K. M.; Paranjape, T.; Nallur, S.; Wouters, K. A.; Weijenberg, M. P.; Schouten, L. J.; van den Brandt, P. A.; Bosman, F. T.; Weidhaas, J. B.; van Engeland, M. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin. Cancer Res. 2011, 17 (24), 7723-7731.
98. Izzotti, A.; Calin, G. A.; Steele, V. E.; Croce, C. M.; De Flora, S. Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. FASEB J. 2009, 23 (9), 3243-3250.
99. Izzotti, A.; Calin, G. A.; Steele, V. E.; Cartiglia, C.; Longobardi, M.; Croce, C. M.; De Flora, S. Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs. Cancer Prev. Res. (Phila) 2010, 3 (1), 62-72.
100. Izzotti, A.; Larghero, P.; Cartiglia, C.; Longobardi, M.; Pfeffer, U.; Steele, V. E.; De Flora, S. Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung. Carcinogenesis 2010, 31 (5), 894-901.
101. Schembri, F.; Sridhar, S.; Perdomo, C.; Gustafson, A. M.; Zhang, X.; Ergun, A.; Lu, J.; Liu, G.; Bowers, J.; Vaziri, C.; Ott, K.; Sensinger, K.; Collins, J. J.; Brody, J. S.; Getts, R.; Lenburg, M. E.; Spira, A. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc. Natl. Acad. Sci. U S A 2009, 106 (7), 2319-2324.
102. Landi, M. T.; Zhao, Y.; Rotunno, M.; Koshiol, J.; Liu, H.; Bergen, A. W.; Rubagotti, M.; Goldstein, A. M.; Linnoila, I.; Marincola, F. M.; Tucker, M. A.; Bertazzi, P. A.; Pesatori, A. C.; Caporaso, N. E.; McShane, L. M.; Wang, E. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 2010, 16 (2), 430-441.
103. Russ, R.; Slack, F. J. Cigarette-smoke-induced dysregulation of microRNA expression and its role in lung carcinogenesis. Pulm. Med. 2012, 2012, 791234.
104. Davidson, M. R.; Larsen, J. E.; Yang, I. A.; Hayward, N. K.; Clarke, B. E.; Duhig, E. E.; Passmore, L. H.; Bowman, R. V.; Fong, K. M. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One 2010, 5 (9), e12560.
105. Xi, S.; Yang, M.; Tao, Y.; Xu, H.; Shan, J.; Inchauste, S.; Zhang, M.; Mercedes, L.; Hong, J. A.; Rao, M.; Schrump, D. S. Cigarette smoke induces C/EBP-beta-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS One 2010, 5 (10), e13764.
106. Shin, V. Y.; Jin, H.; Ng, E. K.; Cheng, A. S.; Chong, W. W.; Wong, C. Y.; Leung, W. K.; Sung, J. J.; Chu, K. M. NF-kappaB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. Carcinogenesis 2011, 32 (2), 240-245.
107. Izzotti, A.; Calin, G. A.; Arrigo, P.; Steele, V. E.; Croce, C. M.; De Flora, S. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 2009, 23 (3), 806-812.
108. Wang, X. C.; Du, L. Q.; Tian, L. L.; Wu, H. L.; Jiang, X. Y.; Zhang, H.; Li, D. G.; Wang, Y. Y.; Wu, H. Y.; She, Y.; Liu, Q. F.; Fan, F. Y.; Meng, A. M. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 2011, 72 (1), 92-99.
109. Kato, M.; Paranjape, T.; Muller, R. U.; Nallur, S.; Gillespie, E.; Keane, K.; Esquela-Kerscher, A.; Weidhaas, J. B.; Slack, F. J. The miR-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009, 28 (25), 2419-2424.
110. Tili, E.; Michaille, J. J.; Wernicke, D.; Alder, H.; Costinean, S.; Volinia, S.; Croce, C. M. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc. Natl. Acad. Sci. U S A 2011, 108 (12), 4908-4913.
111. Zhang, Y.; Wei, W.; Cheng, N.; Wang, K.; Li, B.; Jiang, X.; Sun, S. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012. [Epub Ahead of print].
112. Braconi, C.; Valeri, N.; Gasparini, P.; Huang, N.; Taccioli, C.; Nuovo, G.; Suzuki, T.; Croce, C. M.; Patel, T. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 2010, 16 (3), 957-966.
113. Young, D. D.; Connelly, C. M.; Grohmann, C.; Deiters, A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc. 2010, 132 (23), 7976-7981.
114. Banaudha, K.; Kaliszewski, M.; Korolnek, T.; Florea, L.; Yeung, M. L.; Jeang, K. T.; Kumar, A. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology 2011, 53 (1), 53-61.
115. Wang, X.; Wang, H. K.; McCoy, J. P.; Banerjee, N. S.; Rader, J. S.; Broker, T. R.; Meyers, C.; Chow, L. T.; Zheng, Z. M. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009, 15 (4), 637-647.
116. Yu, H.; Lu, J.; Zuo, L.; Yan, Q.; Yu, Z.; Li, X.; Huang, J.; Zhao, L.; Tang, H.; Luo, Z.; Liao, Q.; Zeng, Z.; Zhang, J.; Li, G. Epstein-Barr virus downregulates microRNA 203 through the oncoprotein latent membrane protein 1: a contribution to increased tumor incidence in epithelial cells. J. Virol. 2012, 86 (6), 3088-3099.
117. Di Leva, G.; Gasparini, P.; Piovan, C.; Ngankeu, A.; Garofalo, M.; Taccioli, C.; Iorio, M. V.; Li, M.; Volinia, S.; Alder, H.; Nakamura, T.; Nuovo, G.; Liu, Y.; Nephew, K. P.; Croce C. M. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J. Natl. Cancer. Inst. 2010, 102(10), 706-721.
118. Lu, Y.; Roy, S.; Nuovo, G.; Ramaswamy, B.; Miller, T.; Shapiro, C.; Jacob, S. T.; Majumder, S. Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J. Biol. Chem. 2011, 286(49), 42292-42302.
119. Marsit, C. J.; Eddy, K.; Kelsey, K. T. MicroRNA responses to cellular stress. Cancer Res. 2006, 66(22), 10843-10848.
120. Greenberg, E.; Rechavi, G.; Amariglio, N.; Solomon, O.; Schachter, J.; Markel, G.; Eyal, E. Mutagen-specific mutation signature determines global microRNA binding. PLoS One 2011, 6(11), e27400.
121. Aypar, U.; Morgan, W. F.; Baulch, J. E. Radiation-induced epigenetic alterations after low and high LET irradiations. Mutat. Res. 2011, 707(1-2), 24-33.
122. Wang, V.; Wu, W. MicroRNA-based therapeutics for cancer. BioDrugs 2009, 23(1), 15-23.
123. Mascaux, C.; Laes, J. F.; Anthoine, G.; Haller, A.; Ninane, V.; Burny, A.; Sculier, J. P. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur. Respir. J. 2009, 33(2), 352-359.
124. Wilting, S. M.; Snijders, P. J.; Verlaat, W.; Jaspers, A.; van de Wiel, M. A.; van Wieringen, W. N.; Meijer, G. A.; Kenter, G. G.; Yi, Y.; le Sage, C.; Agami, R.; Meijer, C. J.; Steenbergen, R. D. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene. 2013, 32(1), 106-116.
125. Lanza, G.; Ferracin, M.; Gafa, R.; Veronese, A.; Spizzo, R.; Pichiorri, F.; Liu, C. G.; Calin, G. A.; Croce, C. M.; Negrini, M. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer 2007, 6, 54.
126. Chang, K. H.; Miller, N.; Kheirelseid, E. A.; Lemetre, C.; Ball, G. R.; Smith, M. J.; Regan, M.; McAnena, O. J.; Kerin, M. J. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int. J. Colorectal Dis. 2011, 26(11), 1415-1422.
127. Chen, X.; Hu, Z.; Wang, W.; Ba, Y.; Ma, L.; Zhang, C.; Wang, C.; Ren, Z.; Zhao, Y.; Wu, S.; Zhuang, R.; Zhang, Y.; Hu, H.; Liu, C.; Xu, L.; Wang, J.; Shen, H.; Zhang, J.; Zen, K.; Zhang, C. Y. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int. J. Cancer 2012, 130(7), 1620-1628.
128. Hennessey, P. T.; Sanford, T.; Choudhary, A.; Mydlarz, W. W.; Brown, D.; Adai, A. T.; Ochs, M. F.; Ahrendt, S. A.; Mambo, E.; Califano, J. A. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 2012, 7(2), e32307.
129. Moltzahn, F.; Olshen, A. B.; Baehner, L.; Peek, A.; Fong, L.; Stoppler, H.; Simko, J.; Hilton, J. F.; Carroll, P.; Blelloch, R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011, 71(2), 550-560.
130. Ali, S.; Almhanna, K.; Chen, W.; Philip, P. A.; Sarkar, F. H. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am. J. Transl. Res. 2010, 3(1), 28-47.
131. Tan, X.; Qin, W.; Zhang, L.; Hang, J.; Li, B.; Zhang, C.; Wan, J.; Zhou, F.; Shao, K.; Sun, Y.; Wu, J.; Zhang, X.; Qiu, B.; Li, N.; Shi, S.; Feng, X.; Zhao, S.; Wang, Z.; Zhao, X.; Chen, Z.; Mitchelson, K.; Cheng, J.; Guo, Y.; He, J. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin. Cancer Res. 2011, 17(21), 6802-6811.
132. Li, Y.; Li, W.; Ouyang, Q.; Hu, S.; Tang, J: Detection of lung cancer with blood microRNA-21 expression levels in Chinese population. Oncol. Lett. 2011, 2(5), 991-994.
133. Wei, J.; Gao, W.; Zhu, C. J.; Liu, Y. Q.; Mei, Z.; Cheng, T.; Shu, Y. Q. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin. J. Cancer 2011, 30(6), 407-414.
134. Cui, E. H.; Li, H. J.; Hua, F.; Wang, B.; Mao, W.; Feng, X. R.; Li, J. Y.; Wang, X. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol. Sin. 2012. [Epub Ahead of print].
135. Xie, Y.; Todd, N. W.; Liu, Z.; Zhan, M.; Fang, H.; Peng, H.; Alattar, M.; Deepak, J.; Stass, S. A.; Jiang, F. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67 (2), 170-176.
136. Lee, J. A.; Lee, H. Y.; Lee, E. S.; Kim, I.; Bae, J. W. Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. J. Breast Cancer 2011, 14 (4), 69-275.
137. Asaga, S.; Kuo, C.; Nguyen, T.; Terpenning, M.; Giuliano, A. E.; Hoon, D. S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011, 57 (1), 84-91.
138. Guo, L. J.; Zhang, Q. Y. Decreased serum miR-181a is a potential new tool for breast cancer screening. Int. J. Mol. Med. 2012, 30 (3), 680-686.
139. Resnick, K. E.; Alder, H.; Hagan, J. P.; Richardson, D. L.; Croce, C. M.; Cohn, D. E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 2009, 112 (1), 55-59.
140. Song, Y. X.; Yue, Z. Y.; Wang, Z. N.; Xu, Y. Y.; Luo, Y.; Xu, H. M.; Zhang, X.; Jiang, L.; Xing, C. Z.; Zhang, Y. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol. Cancer 2011, 10, 1.
141. Li, C.; Li, J. F.; Cai, Q.; Qiu, Q. Q.; Yan, M.; Liu, B. Y.; Zhu, Z. G. MiRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann. Surg. Oncol. 2012. [Epub Ahead of print].
142. Liu, H.; Zhu, L.; Liu, B.; Yang, L.; Meng, X.; Zhang, W.; Ma, Y.; Xiao, H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012, 316 (2), 196-203.
143. Liu, R.; Zhang, C.; Hu, Z.; Li, G.; Wang, C.; Yang, C.; Huang, D.; Chen, X.; Zhang, H.; Zhuang, R.; Deng, T.; Liu, H.; Yin, J.; Wang, S.; Zen, K.; Ba, Y.; Zhang, C. Y. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 2011, 47 (5), 784-791.
144. Zhang, X.; Cui, L.; Ye, G.; Zheng, T.; Song, H.; Xia, T.; Yu, X.; Xiao, B.; Le, Y.; Guo, J. Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol. 2012, 33 (6), 2349-2355.
145. Zhang, T.; Zhao, D.; Wang, Q.; Yu, X.; Cui, Y.; Guo, L.; Lu, S. H. MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Mol. Carcinog. 2012 [Epub Ahead of print].
146. Dai, X.; Chiang, Y.; Wang, Z.; Song, Y.; Lu, C.; Gao, P.; Xu, H. Expression levels of microRNA-375 in colorectal carcinoma. Mol. Med. Report 2012, 5 (5), 1299-1304.
147. Liu, K.; Li, G.; Fan, C.; Zhou, X.; Wu, B.; Li, J. Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer. J. Int. Med. Res. 2011, 39 (6), 2288-2295.
148. Song, Y.; Xu, Y.; Wang, Z.; Chen, Y.; Yue, Z.; Gao, P.; Xing, C.; Xu, H. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int. J. Cancer 2012, 131 (5), 1042-1051.
149. Habbe, N.; Koorstra, J. B.; Mendell, J. T.; Offerhaus, G. J.; Ryu, J. K.; Feldmann, G.; Mullendore, M. E.; Goggins, M. G.; Hong, S. M.; Maitra, A. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther. 2009, 8 (4), 340-346.
150. Tomimaru, Y.; Eguchi, H.; Nagano, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Tanemura, M.; Tomokuni, A.; Takemasa, I.; Umeshita, K.; Kanto, T.; Doki, Y.; Mori, M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J. Hepatol. 2012, 56 (1), 167-175.
151. Wulfken, L. M.; Moritz R.; Ohlmann, C.; Holdenrieder, S.; Jung, V.; Becker, F.; Herrmann, E.; Walgenbach-Brunagel, G.; von Ruecker, A.; Muller, S. C.; Ellinger, J. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011, 6 (9), e25787.
152. Avissar, M.; Christensen, B. C.; Kelsey, K. T.; Marsit, C. J. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin. Cancer Res. 2009, 15 (8), 2850-2855.
153. Gong, M.; Ma, J.; Li, M.; Zhou, M.; Hock, J. M.; Yu, X. MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors. Neuro. Oncol. 2012, 14 (8), 1007-1017.
154. Wang, B.; Zhang, Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol. 2012, 138 (10), 1659-1666.
155. Snowdon, J.; Boag, S.; Feilotter, H.; Izard, J.; Siemens, D. R. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can. Urol. Assoc. J. 2012, 1-5.
156. Yang, C.; Wang, C.; Chen, X.; Chen, S.; Zhang, Y.; Zhi, F.; Wang, J.; Li, L.; Zhou, X.; Li, N.; Pan, H.; Zhang, J.; Zen, K.; Zhang, C. Y.; Zhang, C. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int. J. Cancer 2013, 132 (1), 116-127.
157. Schrauder, M. G.; Strick, R.; Schulz-Wendtland, R.; Strissel, P. L.; Kahmann, L.; Loehberg, C. R.; Lux, M. P.; Jud, S. M.; Hartmann, A.; Hein, A.; Bayer, C. M.; Bani, M. R.; Richter, S.; Adamietz, B. R.; Wenkel, E.; Rauh, C.; Beckmann, M. W.; Fasching, P. A. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PloS One 2012, 7 (1), e29770.
158. Michael, A.; Bajracharya, S. D.; Yuen, P. S.; Zhou, H.; Star, R. A.; Illei, G. G.; Alevizos, I. Exosomes from human saliva as a source of microRNA biomarkers. Oral. Diseases 2010, 16 (1), 34-38.
159. Park, N. J.; Zhou, H.; Elashoff, D.; Henson, B. S.; Kastratovic, D. A.; Abemayor, E.; Wong, D. T. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 2009, 15 (17), 5473-5477.
160. Weber, J. A.; Baxter, D. H.; Zhang, S.; Huang, D. Y.; Huang, K. H.; Lee, M. J.; Galas, D. J.; Wang, K., The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56 (11), 1733-1741.
161. Link, A.; Balaguer, F.; Shen, Y.; Nagasaka, T.; Lozano, J. J.; Boland, C. R.; Goel, A. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev. 2010, 19 (7), 1766-1774.
162. Bryant, R. J.; Pawlowski, T.; Catto, J. W.; Marsden, G.; Vessella, R. L.; Rhees, B.; Kuslich, C.; Visakorpi, T.; Hamdy, F. C. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106 (4), 768-774.
163. Miah, S.; Dudziec, E.; Drayton, R. M.; Zlotta, A. R.; Morgan, S. L.; Rosario, D. J.; Hamdy, F. C.; Catto, J. W. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br. J. Cancer 2012, 107 (1), 123-128.
164. Kunte, D. P.; Delacruz, M.; Wali, R. K.; Menon, A.; Du, H.; Stypula, Y.; Patel, A.; Backman, V.; Roy, H. K. Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening. PLoS One 2012, 7 (9), e45591.
165. Saito, M.; Schetter, A. J.; Mollerup, S.; Kohno, T.; Skaug, V.; Bowman, E. D.; Mathe, E. A.; Takenoshita, S.; Yokota, J.; Haugen, A.; Harris, C. C. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin. Cancer Res. 2011, 17 (7), 1875-1882.
166. Liu, X. G.; Zhu, W. Y.; Huang, Y. Y.; Ma, L. N.; Zhou, S. Q.; Wang, Y. K.; Zeng, F.; Zhou, J. H.; Zhang, Y. K. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. 2012, 29 (2), 618-626.
167. Liu, Z. L.; Wang, H.; Liu, J.; Wang, Z. X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol. Cell Biochem. 2012, 372 (1-2), 35-45.
168. Qian, B.; Katsaros, D.; Lu, L.; Preti, M.; Durando, A.; Arisio, R.; Mu, L.; Yu, H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res. Treat. 2009, 117 (1), 131-140.
169. Takamizawa, J.; Konishi, H.; Yanagisawa, K.; Tomida, S.; Osada, H.; Endoh, H.; Harano, T.; Yatabe, Y.; Nagino, M.; Nimura, Y.; Mitsudomi, T.; Takahashi, T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64 (11), 3753-3756.
170. Ranade, A. R.; Cherba, D.; Sridhar, S.; Richardson, P.; Webb, C.; Paripati, A.; Bowles, B.; Weiss, G. J. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J. Thorac. Oncol. 2010, 5 (8), 1273-1278.
171. Wang, T.; Lv, M.; Shen, S.; Zhou, S.; Wang, P.; Chen, Y.; Liu, B.; Yu, L.; Hou, Y. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS One 2012, 7 (8), e43268.
172. Chen, L. T.; Xu, S. D.; Xu, H.; Zhang, J. F.; Ning, J. F.; Wang, S.F. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med. Oncol. 2012, 29 (3), 1673-1680.
173. Zhou, X.; Marian, C.; Makambi, K. H.; Kosti, O.; Kallakury, B. V.; Loffredo, C. A.; Zheng, Y. L. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One 2012, 7 (6), e39011.
174. Rothe, F.; Ignatiadis, M.; Chaboteaux, C.; Haibe-Kains, B.; Kheddoumi, N.; Majjaj, S.; Badran, B.; Fayyad-Kazan, H.; Desmedt, C.; Harris, A. L. et al: Global microRNA expression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011, 6 (6), e20980.
175. Zhao, F. L.; Hu, G. D.; Wang, X. F.; Zhang, X. H.; Zhang, Y. K.; Yu, Z. S. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J. Int. Med. Res. 2012, 40(3), 859-866.
176. Pichler, M.; Winter, E.; Stotz, M.; Eberhard, K.; Samonigg, H.; Lax, S.; Hoefler, G. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br. J. Cancer 2012, 106 (11), 1826-1832.
177. Wang, L. G.; Gu, J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012, 36 (1), e61-67.
178. Cheng, H.; Zhang, L.; Cogdell, D. E.; Zheng, H.; Schetter, A. J.; Nykter, M.; Harris, C. C.; Chen, K.; Hamilton, S. R.; Zhang, W. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6 (3), e17745.
179. Han, Z. B.; Chen, H. Y.; Fan, J. W.; Wu, J. Y.; Tang, H. M.; Peng, Z. H. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J. Cancer Res. Clin. Oncol. 2012, 138 (1), 153-161.
180. Inoue, T.; Iinuma, H.; Ogawa, E.; Inaba, T.; Fukushima, R. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol. Rep. 2012, 27 (6), 1759-1764.
181. Hwang, J. H.; Voortman, J.; Giovannetti, E.; Steinberg, S. M.; Leon, L. G.; Kim, Y. T.; Funel, N.; Park, J. K.; Kim, M. A.; Kang, G.H.; Kim, S. W.; Del Chiaro, M.; Peters G. J.; Glaccone G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010, 5 (5), e10630.
182. Papaconstantinou, I. G.; Manta, A.; Gazouli, M.; Lyberopoulou, A.; Lykoudis, P. M.; Polymeneas, G.; Voros, D. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 2012.
183. Lin, D.; Cui, F.; Bu, Q.; Yan, C. The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer. J. Int. Med. Res. 2011, 39 (5), 1870-1875.
184. Karaayvaz, M.; Zhang, C.; Liang, S.; Shroyer, K. R.; Ju, J. Prognostic significance of miR-205 in endometrial cancer. PLoS One 2012, 7(4), e35158.
185. Yang, N.; Kaur, S.; Volinia, S.; Greshock, J.; Lassus, H.; Hasegawa, K.; Liang, S.; Leminen, A.; Deng, S.; Smith, L.; Johnstone, C. N.; Chen, X. M.; Liu, C. G.; Huang, Q.; Katsaros, D.; Calin, G. A.; Weber, B. L.; Butzow, R.; Croce, C. M.; Coukos, G.; Zhang, L. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008, 68 (24), 10307-10314.
186. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R. M.; Okamoto, A.; Yokota, J.; Tanaka, T.; Calin, G. A.; Liu, C. G.; Croce, C. M.; Harris, C. C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9 (3), 189-198.
187. Jay, C.; Nemunaitis, J.; Chen, P.; Fulgham, P.; Tong, A. W. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007, 26 (5), 293-300.
188. Raponi, M.; Dossey, L.; Jatkoe, T.; Wu, X.; Chen, G.; Fan, H.; Beer, D. G. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009, 69 (14), 5776-5783.
189. Ueda, T.; Volinia, S.; Okumura, H.; Shimizu, M.; Taccioli, C.; Rossi, S.; Alder, H.; Liu, C. G.; Oue, N.; Yasui, W.; Yoshida, K.; Sasaki, H.; Nomura, S.; Seto, Y.; Kaminishi, M.; Calin, G. A.; Croce, C. M. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet. Oncol. 2010, 11 (2), 136-146.
190. Volinia, S.; Galasso, M.; Sana, M. E.; Wise, T. F.; Palatini, J.; Huebner, K.; Croce, C. M. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc. Natl. Acad. Sci. U S A 2012, 109 (8), 3024-3029.
191. Chen, J.; Tian, W.; Cai, H.; He, H.; Deng, Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med. Oncol. 2012, 29 (4), 2527-2534.
192. Zhu, W.; Zhu, D.; Lu, S.; Wang, T.; Wang, J.; Jiang, B.; Shu, Y.; Liu, P. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med. Oncol. 2012, 29 (1), 384-391.
193. Nahta, R.; Takahashi, T.; Ueno, N. T.; Hung, M. C.; Esteva, F. J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004, 64 (11), 3981-3986.
194. Garofalo, M.; Quintavalle, C.; Romano, G.; Croce, C. M.; Condorelli, G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr. Mol. Med. 2012, 12 (1), 27-33.
195. Weiss, G. J.; Bemis, L. T.; Nakajima, E.; Sugita, M.; Birks, D. K.; Robinson, W. A.; Varella-Garcia, M.; Bunn, P. A., Jr.; Haney, J.; Helfrich, B. A.; Kato, H.; Hirsch, F. R.; Franklin, W. A. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 2008, 19 (6), 1053-1059.
196. Seike, M.; Goto, A.; Okano, T.; Bowman, E. D.; Schetter, A. J.; Horikawa, I.; Mathe, E. A.; Jen, J.; Yang, P.; Sugimura, H.; Gemma, A.; Kudoh, S.; Croce, C. M.; Harris, C. C. miR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. U S A 2009, 106 (29), 12085-12090.
197. Giovannetti, E.; Erozenci, A.; Smit, J.; Danesi, R.; Peters, G. J. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 2012, 81 (2), 103-122.
198. Wang, H.; Tan, G.; Dong, L.; Cheng, L.; Li, K.; Wang, Z.; Luo, H. Circulating miR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012, 7 (4), e34210.
199. Preis, M.; Gardner, T. B.; Gordon, S. R.; Pipas, J. M.; Mackenzie, T. A.; Klein, E. E.; Longnecker, D. S.; Gutmann, E. J.; Sempere, L. F.; Korc, M. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2011, 17 (17), 5812-5821.
200. Jung, E. J.; Santarpia, L.; Kim, J.; Esteva, F. J.; Moretti, E.; Buzdar, A. U.; Di Leo, A.; Le, X. F.; Bast, R. C. Jr.; Park, S. T.; Pusztai, L.; Calin, G. A. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012, 118 (10), 2603-2614.
201. Zhang, H. L.; Yang, L. F.; Zhu, Y.; Yao, X. D.; Zhang, S. L.; Dai, B.; Zhu, Y. P.; Shen, Y. J.; Shi, G. H.; Ye, D. W. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011, 71 (3), 326-331.
202. Parasramka, M. A.; Ho, E.; Williams, D. E.; Dashwood, R. H. MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol. Carcinog. 2012, 51 (3), 213-230.
203. Beveridge, N. J.; Tooney, P. A.; Carroll, A. P.; Tran, N.; Cairns, M. J. Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell. Signal 2009, 21 (12), 1837-1845.
204. Chen, W. S.; Hou, J. N.; Guo, Y. B.; Yang, H. L.; Xie, C. M.; Lin, Y. C.; She, Z. G. Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway. J. Exp. Clin. Cancer Res. 2011, 30, 17.
205. Verbrugge, I.; Johnstone, R. W.; Bots, M. Promises and challenges of anticancer drugs that target the epigenome. Epigenomics 2011, 3 (5), 547-565.
206. Sun, S. Y.; Lotan, R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol. 2002, 41 (1), 41-55.
207. Rossi, A.; D'Urso, O. F.; Gatto, G.; Poltronieri, P.; Ferracin, M.; Remondelli, P.; Negrini, M.; Caporaso, M. G.; Bonatti, S.; Mallardo, M. Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4. BMC Res. Notes 2010, 3, 24.
208. Terao, M.; Fratelli, M.; Kurosaki, M.; Zanetti, A.; Guarnaccia, V.; Paroni, G.; Tsykin, A.; Lupi, M.; Gianni, M.; Goodall, G. J.; Garattini, E. Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets. J. Biol. Chem. 2011, 286 (5), 4027-4042.
209. Kawasaki, H.; Taira, K. Functional analysis of microRNAs during the retinoic acid-induced neuronal differentiation of human NT2 cells. Nucleic Acids Res. Suppl. 2003, 3, 243-244.
210. Razumilava, N.; Bronk, S. F.; Smoot, R. L.; Fingas, C. D.; Werneburg, N. W.; Roberts, L. R.; Mott, J. L. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 2012, 55 (2), 465-475.
211. Kutay, H.; Bai, S.; Datta, J.; Motiwala, T.; Pogribny, I.; Frankel, W.; Jacob, S. T.; Ghoshal, K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 2006, 99 (3), 671-678.
212. Wang, L. L.; Zhang, Z.; Li, Q.; Yang, R.; Pei, X.; Xu, Y.; Wang, J.; Zhou, S. F.; Li, Y. Ethanol exposure induces differential microRNA and target gene expression and teratogenic effects which can be suppressed by folic acid supplementation. Hum. Reprod. 2009, 24 (3), 562-579.
213. Wang, X.; Gocek, E.; Liu, C. G.; Studzinski, G. P. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009, 8 (5), 736-741.
214. Gocek, E.; Wang, X.; Liu, X.; Liu, C. G.; Studzinski, G. P. MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res. 2011, 71(19), 6230-6239.
215. Peng, X.; Vaishnav, A.; Murillo, G.; Alimirah, F.; Torres, K. E.; Mehta, R. G. Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J. Cell. Biochem. 2010, 110 (6), 1324-1333.
216. Wang, J.; Li, J.; Shen, J.; Wang, C.; Yang, L.; Zhang, X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012, 12 (1), 227.
217. Mohri, T.; Nakajima, M.; Takagi, S.; Komagata, S.; Yokoi, T. MicroRNA regulates human vitamin D receptor. Int. J. Cancer 2009, 125 (6), 1328-1333.
218. Davis, C. D.; Milner, J. A. Nutrigenomics, vitamin D and cancer prevention. J. Nutrigenet. Nutrigenomics 2011, 4 (1), 1-11.
219. Gaedicke, S.; Zhang, X.; Schmelzer, C.; Lou, Y.; Doering, F.; Frank, J.; Rimbach, G. Vitamin E dependent microRNA regulation in rat liver. FEBS Lett. 2008, 582 (23-24), 3542-3546.
220. Rimbach, G.; Moehring, J.; Huebbe, P.; Lodge, J. K. Gene-regulatory activity of alpha-tocopherol. Molecules 2010, 15 (3), 1746-1761.
221. Davidson, L. A.; Wang, N.; Shah, M. S.; Lupton, J. R.; Ivanov, I.; Chapkin, R. S. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis 2009, 30 (12), 2077-2084.
222. Tzur, G.; Levy, A.; Meiri, E.; Barad, O.; Spector, Y.; Bentwich, Z.; Mizrahi, L.; Katzenellenbogen, M.; Ben-Shushan, E.; Reubinoff, B. E.; Galun, E. MicroRNA expression patterns and function in endodermal differentiation of human embryonic stem cells. PloS One 2008, 3 (11), e3726.
223. Hu, S.; Dong, T. S.; Dalal, S. R.; Wu, F.; Bissonnette, M.; Kwon, J. H.; Chang, E. B. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PloS One 2011, 6 (1), e16221.
224. Sarveswaran, S.; Liroff, J.; Zhou, Z.; Nikitin, A. Y.; Ghosh, J. Selenite triggers rapid transcriptional activation of p53, and p53-mediated apoptosis in prostate cancer cells: Implication for the treatment of early-stage prostate cancer. Int. J Oncol. 2010, 36 (6), 1419-1428.
225. Alpers, D. H. Garlic and its potential for prevention of colorectal cancer and other conditions. Curr. Opin. Gastroenterol. 2009, 25 (2), 116-121.
226. Noratto, G. D.; Kim, Y.; Talcott, S. T.; Mertens-Talcott, S. U. Flavonol-rich fractions of yaupon holly leaves (Ilex vomitoria, Aquifoliaceae) induce microRNA-146a and have anti-inflammatory and chemopreventive effects in intestinal myofibroblast CCD-18Co cells. Fitoterapia 2011, 82 (4), 557-569.
227. Shukla, Y. Tea and cancer chemoprevention: a comprehensive review. Asian Pac. J. Cancer Prev. 2007, 8 (2), 155-166.
228. Wen, X. Y.; Wu, S. Y.; Li, Z. Q.; Liu, Z. Q.; Zhang, J. J.; Wang, G. F.; Jiang, Z. H.; Wu, S. G. Ellagitannin (BJA3121), an anti-proliferative natural polyphenol compound, can regulate the expression of MiRNAs in HepG2 cancer cells. Phytother. Res. 2009, 23(6), 778-784.
229. Tsang, W. P.; Kwok, T. T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem. 2010, 21 (2), 140-146.
230. Arola-Arnal, A.; Blade, C. Proanthocyanidins modulate microRNA expression in human HepG2 cells. PloS One 2011, 6(10), e25982.
231. Fix, L. N.; Shah, M.; Efferth, T.; Farwell, M. A.; Zhang, B. MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60. Cancer Genomics & Proteomics 2010, 7 (5), 261-277.
232. Wang, H.; Bian, S.; Yang, C. S. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 2011, 32 (12), 1881-1889.
233. Whitlock, N. C.; Baek, S. J. The anticancer effects of resveratrol: modulation of transcription factors. Nutr. Cancer 2012, 64(4), 493-502.
234. Dhar, S.; Hicks, C.; Levenson, A. S. Resveratrol and prostate cancer: promising role for microRNAs. Mol. Nutr. Food Res. 2011, 55 (8), 1219-1229.
235. Bae, S.; Lee, E. M.; Cha, H. J.; Kim, K.; Yoon, Y.; Lee, H.; Kim, J.; Kim, Y. J.; Lee, H. G.; Jeung, H. K.; Min, Y. H.; An, S. Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells. Mol. Cells 2011, 32 (3), 243-249.
236. Tili, E.; Michaille, J. J. Resveratrol, MicroRNAs, Inflammation, and Cancer. J. Nucleic Acids 2011, 2011, 102431.
237. Tili, E.; Michaille, J. J.; Alder, H.; Volinia, S.; Delmas, D.; Latruffe, N.; Croce, C. M. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGF beta signaling pathway in SW480 cells. Biochem. Pharmacol. 2010, 80 (12), 2057-2065.
238. Tili, E.; Michaille, J. J.; Adair, B.; Alder, H.; Limagne, E.; Taccioli, C.; Ferracin, M.; Delmas, D.; Latruffe, N.; Croce, C. M. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010, 31 (9), 1561-1566.
239. Han, Z.; Yang, Q.; Liu, B.; Wu, J.; Li, Y.; Yang, C.; Jiang, Y. MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis 2012, 33(1), 131-139.
240. Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A. B.; Aggarwal, B. B. Curcumin and cancer: an old-age disease with an age-old solution. Cancer Lett. 2008, 267 (1), 133-164.
241. Sun, M.; Estrov, Z.; Ji, Y.; Coombes, K. R.; Harris, D. H.; Kurzrock, R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 2008, 7 (3), 464-473.
242. Yang, J.; Cao, Y.; Sun, J.; Zhang, Y. Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med. Oncol. 2010, 27 (4), 1114-1118.
243. Zhang, J.; Du, Y.; Wu, C.; Ren, X.; Ti, X.; Shi, J.; Zhao, F.; Yin, H. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol. Rep. 2010, 24 (5), 1217-1223.
244. Mudduluru, G.; George-William, J. N.; Muppala, S.; Asangani, I. A.; Kumarswamy, R.; Nelson, L. D.; Allgayer, H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci. Rep. 2011, 31 (3), 185-197.
245. Saini, S.; Arora, S.; Majid, S.; Shahryari, V.; Chen, Y.; Deng, G.; Yamamura, S.; Ueno, K.; Dahiya, R. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev. Res. (Phila.) 2011, 4 (10), 1698-1709.
246. Bao, B.; Ali, S.; Kong, D.; Sarkar, S. H.; Wang, Z.; Banerjee, S.; Aboukameel, A.; Padhye, S.; Philip, P. A.; Sarkar, F. H. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PloS One 2011, 6 (3), e17850.
247. Sun, Q.; Cong, R.; Yan, H.; Gu, H.; Zeng, Y.; Liu, N.; Chen, J.; Wang, B. Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol. Rep. 2009, 22 (3), 563-567.
248. Li, Y.; Vandenboom, T. G., 2nd; Wang, Z.; Kong, D.; Ali, S.; Philip, P. A.; Sarkar, F. H. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010, 70 (4), 1486-1495.
249. Parker, L. P.; Taylor, D. D.; Kesterson, J.; Metzinger, D. S.; Gercel-Taylor, C. Modulation of microRNA associated with ovarian cancer cells by genistein. Eur. J. Gynaecol. Oncol. 2009, 30 (6), 616-621.
250. Majid, S.; Dar, A. A.; Saini, S.; Chen, Y.; Shahryari, V.; Liu, J.; Zaman, M. S.; Hirata, H.; Yamamura, S.; Ueno, K.; Tanaka, Y.; Dahiya, R. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. Cancer Res. 2010, 70 (7), 2809-2818.
251. Li, Y.; Sarkar, F. H. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett. 2002, 186 (2), 157-164.
252. Chen, Y.; Zaman, M. S.; Deng, G.; Majid, S.; Saini, S.; Liu, J.; Tanaka, Y.; Dahiya, R. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev. Res. (Phila) 2011, 4 (1), 76-86.
253. Li, Y.; VandenBoom, T. G., 2nd; Kong, D.; Wang, Z.; Ali, S.; Philip, P. A.; Sarkar, F. H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69 (16), 6704-6712.
254. Lin, L. F.; Chiu, S. P.; Wu, M. J.; Chen, P. Y.; Yen, J. H. Luteolin induces microRNA-132 expression and modulates neurite outgrowth in PC12 cells. PloS One 2012, 7 (8), e43304.
255. Izzotti, A.; Cartiglia, C.; Steele, V. E.; De Flora, S. MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat. Res. 2012, 751 (2), 287-303.
256. Wu, N.; Wu, G. C.; Hu, R.; Li, M.; Feng, H. Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol. Sin. 2011, 32(3), 345-353.
257. Chan, L. S.; Yue, P. Y.; Mak, N. K.; Wong, R. N. Role of microRNA-214 in ginsenoside-Rg1-induced angiogenesis. Eur. J. Pharm. Sci. 2009, 38 (4), 370-377.
258. Saleem, M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett. 2009, 285 (2), 109-115.
259. Liu, D.; Dai, C.; Xu, D. Cluster analysis of MiRNAs microarray data and prediction of lupeol's anti-cancer path. BIBM Workshops 2011, 440-445.
260. Rao, A. V., Lycopene, tomatoes, and the prevention of coronary heart disease. Exp Biol Med (Maywood) 2002, 227 (10), 908-13.
261. Ahn, J.; Lee, H.; Jung, C. H.; Ha, T., Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol. Nutr. Food Res. 2012, 56 (11), 1665-1674.
262. Zhang, S.; Won, Y. K.; Ong, C. N.; Shen, H. M. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Anti-Cancer Agents Med. Chem. 2005, 5 (3), 239-249.
263. Zhang, S.; Liu, Q.; Liu, Y.; Qiao, H., Zerumbone, a Southeast Asian Ginger Sesquiterpene, Induced Apoptosis of Pancreatic Carcinoma Cells through p53 Signaling Pathway. Evidence-based complementary and alternative medicine: eCAM 2012, 2012, 936030.
264. Li, L. Q.; Li, X. L.; Wang, L.; Du, W. J.; Guo, R.; Liang, H. H.; Liu, X.; Liang, D. S.; Lu, Y. J.; Shan, H. L.; Jiang, H. C. Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell. Physiol. BBiochem. 2012, 30 (3), 631-641.
265. Stenvang, J.; Petri, A.; Lindow, M.; Obad, S.; Kauppinen, S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012, 3 (1), 1.
266. Aggarwal, B. B.; Kumar, A; Bharti, A. C. Anticancer potential of curcumin: preclinical and clinical studies Anticancer Res. 2003, 23 (1A), 363-398.
267. Carroll, R.E, Benya, R.V.; Turgeon, D.K.; Vareed, S.; Neuman M.; Rodriguez, L.; Kakarala M.; Carpenter, P.M.; McLaren C.; Meyskens F.L. Jr.; Brenner D.E.; (2011) Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia. Cancer Prev Res (Phila). 2011, 4, 354-364.
268. Resveratrol for Patients with Colon Cancer. http://clinicaltrials.gov/show/NCT00256334 (Last accessed on December 20, 2012)